Regeneron's Otarmeni was recently FDA approved for patients with OTOF-related hearing loss based on CHORD trial results.
Smithsonian Magazine on MSN
The FDA approves the first-ever gene therapy for deafness, which aims to restore hearing in kids with a rare inherited condition
On April 23, the Food and Drug Administration approved the first-ever gene therapy for a rare, congenital form of deafness. The treatment’s maker, biotechnology company Regeneron, says it plans to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results